Genotropin

In addition to the above ASRM recommendations, since all oocytes may not fertilize when GIFT is performed, one more oocyte than embryo may be transferred for each prognostic category. Low-Birth-Weight and Multiple Births: The use of assisted reproductive technology has been reported to be a contributor to the rate of low-birth-weight in the United States as it has been associated with a higher rate of multiple births. Additionally, studies have suggested that there is a higher rate of low-birthweight among singleton infants conceived with assisted reproductive technology than among naturally conceived singleton infants or among all infants in the general population Schieve, et al., 2002 ; . In 2002, Schieve et al. used population-based data 42, 463 infants ; to compare the rates of low-birth-weight less than or equal to 2500 grams ; and very low-birth-weight less than 1500 grams ; among infants conceived through the use of assisted reproductive technology, with rates reported in the general population. The authors concluded that "the use of ART accounts for a disproportionate number of low-birth-weight and very-low-birth-weight infants in the United States in part because of the absolute increases in multiple gestations and in part because of higher rates of low birth weight among singleton infants conceived with this technology" Schieve, et al., 2002 ; . Birth Defects: Several studies have been published evaluating the occurrence of birth defects in children after the use of ART. Currently, the literature is inconsistent in reported outcomes, and in defining a clear relationship to the assisted reproductive technology. Some authors suggest maternal factors may be the cause and not the ART. Hansen et al. 2002 ; reported that infants conceived with ICSI or IVF have twice as high a risk of major birth defect as naturally conceived infants. In a systematic review conducted by Hansen et al. 2005 ; the authors reviewed 25 studies with data relating to the prevalence of birth defects in infants conceived following IVF and or ICSI compared with spontaneously conceived infants. Independent expert reviewers determined whether studies were suitable for inclusion in a meta-analysis. Seven selected studies were identified. Two-thirds of the 25 studies showed a 25% or greater increased risk of birth defects in ART infants. The results of the meta-analysis combined with the 25 studies suggest a statistically significant 30-40% increased risk of birth defects associated with ART. While these authors. Sugar 5 The price support program for sugar is continued with the same nominal support level -18 cents per pound for raw sugar and 22.9 cents per pound for refined sugar-. However, the 2002 Farm Bill effectively increased the support price for sugar by abolishing the penalty for putting sugar under loan and the fee for loan default. These changes have the effect of raising the effective support rate by two cents per pound. Non-recourse loans are authorized for raw and refined sugar products and the loans are extended to in-process beets and cane syrup. However, in the sugar price support program the loans are extended to the processors of sugar beets and sugar cane with the stipulation that the processors pay producers a specified price. If the market price of processed sugar is too low to cover the loan rate plus the interest on the loan the processors turn the sugar over to the government. Then the government has to pay the storage costs and dispose of the sugar, usually at a loss. Thus, if the US government is to avoid acquiring surplus sugar it must maintain the internal price of processed sugar above the loan rate plus the interest and other costs of the processors. The 2002 legislation instructs the Secretary of Agriculture to operate the sugar program at no cost to the treasury by avoiding loan forfeitures under the loan program. The legislation provides two policy instruments to avoid stock accumulation. One is a producer PIK program that will pay producers to plant or market less sugar beets or cane. The other is a marketing allotment program that gives the Secretary of Agriculture the authority to impose marketing allotments on domestic producers to avoid loan forfeitures and to comply with US commitments under the WTO. The tariff rate quotas established under the Uruguay Round provides that the US will allow 1.256 short tons raw value STRV ; of sugar to enter at nominal tariffs. In addition, the NAFTA agreement with Mexico provides that Mexico can ship sugar into the US market at steadily declining tariff levels. The quantity of sugar that Mexico can export to the US is under dispute and has been since the Congress required a side letter with Mexico regarding sugar access to the US market before they would approve the NAFTA agreement.

Omnitrope In July 2003, the Sandoz unit responsible for generics of pharmaceutical giant Novatis filed, and the FDA accepted, an Abbreviated New Drug Application for a "follow-on" version of Pfizer's brand-name human growth hormone named Genotropin that that Sandoz called Omnitrope using the 505 b ; 2 ; pathway. Sandoz was already selling Omnitrope in Australia, and the application was submitted following lengthy discussions with the FDA and contained preclinical, clinical, and comparability data, as well as literature references to the FDA's original decision on Pfizer's Genotropin. But on September 2, 2004, the FDA told Sandoz that the Agency was unable to reach a decision on whether to approve the company's application for Omnitrope. Sandoz provided far more than generic pill manufacturers are required to, yet the FDA refused to take action, first by delaying the decision, then by claiming that Congress needed tell the FDA how it should proceed with regulation on generic proteins, enzymes and antibodies. After two years of regulatory inaction and finger pointing, Sandoz grew frustrated with the FDA's failure to give them a decision on Omnitrope, so they sued the FDA in U.S. District Court in Washington, D.C., citing a statutory requirement that the FDA is required by law to act on drug applications within 180 days. On May 30, 2006, Judge Ricardo Urbina ruled in favor of Sandoz on the Omnitrope case in a very strongly worded opinion, calling the FDA's repeated delays "egregious" noting there was absolutely no excuse for a delay that was nearing 1, 000 days, and effectively ordered the FDA to give the company a response. Following the lawsuit, the FDA approved Omnitrope. In approving the Sandoz drug, the FDA said that it found that the active ingredients in Omnitrope and Genotropin were "highly similar, " therefore the Agency could rely on its previous findings that the Pfizer product was safe and effective in addition to Sandoz's own studies. But the FDA also noted that its approval did not rest exclusively on proprietary information from the original Genotropin application as it does with ordinary chemical drugs. Sandoz told the press that it had submitted an "abbreviated" version of the typical clinical trials the abbreviated trials were done on just 51 people vs. thousands normally required to prove the efficacy of a brand new medicine ; , as well as safety studies and a detailed document outlining how the company planned to manufacture Omnitrope to ensure its quality. Finally, the FDA stated that the law governing generics permits approvals like Omnitrope's because they aren't technically forbidden, "as long as the current state of science allows the evaluation necessary to support approval, " the FDA wrote in its response to Pfizer's petition against Omnitrope's ANDA. The Generic Pharmaceutical Association GPhA ; President and CEO Kathleen Jaeger responded by saying "The FDA's Omnitrope decision clearly demonstrates that sound science exists to support the approval of generic biopharmaceuticals despite assertions from special interests to the contrary." Rep. Waxman's staff also noted that by approving Omnitrope, the Congressman believes the FDA now has provided evidence that generic manufacturers can indeed make biotech copies as good as the original. The GPhA said at the time that the Omnitrope approval was a first step to opening the industry to competition from generics. But according to the governors who sued the FDA in August, while the Omnitrope approval helped, FDA guidelines are still needed to help expedite the process. A spokesman named Brian McClung speaking on behalf of Minnesota Gov. Tim Pawlenty said that before generic insulin products could be released, the FDA must create manufacturing standards, which they have not done. "It's been 22 years, " McClung said. "There is no scientific reason for the FDA not to do this, especially when American patients spend .5 billion a year on insulin.
Otherwise the large gene clusters encoding for their biosynthesis would be an unnecessary burden on the organism, a burden usually deleted through evolutionary processes. "Therefore, " explains Petersen, "having a novel natural product in our hands gives us a unique chance to fish for new targets and detect unknown chemical pathways." At Novartis, natural products drug discovery, which requires experts from many scientific areas--ethnobotanists, mycologists, bacteriologists, microbial geneticists, chemists, fermentation specialists, to name just a few--goes back many decades. NIBR celebrated 60 years of formal natural products research in December 2003, hosting a symposium attended by 230 scientists who discussed active compounds and pharmaceuticals derived from plants, invertebrates, bacteria, and fungi. But the roots of today's Natural Products Unit at Novartis extend back even further, to the individual companies that were later combined to form Novartis: Sandoz, Ciba and Geigy. During the first decades of the 20th century, Arthur Stoll and Albert Hofmann developed ergot-alkaloid chemistry at Sandoz. Synthesis of nicotinic acid diethylamide by Hartmann and Seiberth, and market introduction of the analeptic agent Coramin by Ciba followed in 1924; and in the 1930s, Hofmann synthesized yet another compound, the psychedelic LSD-25. Other natural products-related accomplishments are identified in Figure 1. Compares to: Tavist Novartis ; Packaging & Formulation: 1.34mg and 2.68mg - 100s Description: An ethanolamine antihistamine that may be used for symptomatic relief of histamine-related allergic conditions. Dosage: Human label. For example, lipitor will begin to face competition from generic pravastatin pravachol ; and generic simvastatin zocor ; during 200 changes by the fda to its approach to “ follow-on biologics” could subject genotropin to generic competition and gentamicin.
Tor-G, interface, since stabilization the active conformation of of both receptors is similarly achieved by carboxyl-terminal peptides. It is noteworthy that a conformational change around Lys345occurs upon binding of the carboxyl-terminal peptide from at 340-350 ; to metarhodopsin I1 Dratz et al., 1993 ; . The unc mutation of 549 lymphoma cells, in which receptor and G, are uncoupled, changes the homologous AI-$ * to Pro, which would not have the same conformational flexibility. Thus, conformational change of the G protein carboxyl terminus may be important for productive G protein-receptor interaction and subsequent receptor-mediated GDP releaseand G protein N" 2000 , . activation. c 0 .001 We have shown that two small peptides from the carboxylPeptide mM ; terminal region of a, can each mimic G, effects on P-adrenergic FIG.5. Partial additivity of a, -364-372 and a, -384-394 on in- receptors. Although either peptide can elicit a nearly maximal crease of agonist binding affinity to P-adrenergic receptors in permeable C6 cells. Indicated concentrations of a, -354-372 closed effect, combinations of the two peptides are partially additive squares ; , a, -38&394 closed circles ; , or indicated concentrations of aB- Fig. 51, leading to a multisite model of receptor- .protein in384-394 + 100 p~ a, -35&372 closed triangles ; were incubated with teraction. These data areconsistent with severalpoint-to-point 100 V M isoproterenol and 150 IPIN. This experiment indicatesthat interactions between receptors and G proteins at regions that these peptides may exhibit a partially additive effect on increasing might be some distance from each other on the primary seagonist affinity. Data expressed as lZ5I disintigrationdminute are dprn ; is of of specific IPIN binding and represent the means triplicate determi- quence of the proteins. Thus, it likely that three-dimensional nations from one of three experiments. folding of these proteins is critical for high affinity molecular recognition. This may helpto explain why "consensussethis region Thr-Cys-Ala-Thr ; is found also in a subclass of quences" of receptors and G proteins have not been found, small G proteins related to the ADP-ribosylation factor Sewell despite the wealth of information on primary amino acid sehas and Kahn, 1988 ; . This region of a Thr320-Thr323, recently quences of both protein families. The elegant studies of the t of been shownto be involved in binding o the guanine ring the mechanism of action of mastoparan Higashijima et al., 1988, two- and three-dimensional conforguanine nucleotide Noel et al., 1993 ; . The possibility that this 1991 ; demonstrate that the region also interacts with receptors suggests a putative mech- mation of interacting sitesis critical for the interaction to take some small peptides have anism for receptor-mediated GDP release, since reorientation place. Our studies demonstrate that the ability to fold into the appropriate conformation in the of the guaninebinding side chains would cause a diminution of has confirmed this find- context of a recognition site on the receptor. GDP affinity. Mutagenesis of a, It is noteworthy that either a, -354-372 or a, -384-394 was ing Thomas et al., 1993 ; . Furthermore, comparative studies of able toacheive a maximal effect on increasing P-receptor affininteraction of various classes of GTP binding proteins with their cognate guanine nucleotide exchange factor proteins sug- ity Fig. 5 ; . This suggests that, although multiple sites on G the gest that the exchange factor interacts with the TCAT region, proteins may normally contact P-receptor, occupation of one of which is directly involved in binding the guanine ring Hwang those sites is sufficient to mimic the binding of a G protein. Increasing concentrations of peptide eliminate the ability of et al., 1992, 1993 ; . regions of the G protein may involved GTP to shift receptor into the low affinity state for agonist be It is clear that other in receptor interaction. The amino-terminal region of at was binding. This resultis consistent with the notion of a continushown to be involved in rhodopsin interaction Hamm et al., ous competition between a, and peptide for a bindingsite on the 19881, and this may be the case with other proteins aswell, receptor, which can be overcome by great excess of peptide G since Higashijima et al. 1990 ; have shown that the receptor relative t o a, Fig. 4b ; . Such a mechanism might also be inmimetic tetradecapeptide mastoparan can be cross-linked t o volved in the ability of the a, peptides t o shift the receptor the amino terminus ao.The crystal structure the a subunit into a higher affinity state for agonist. Peptides bind to the of of of G, shows that theamino and carboxyl termini are in spatial appropriate sites to mimic high agonist affinity without disproximity Noel et al., 1993 ; . In this study, amino-terminal playing the comprehensive characteristics of the receptor-G peptides from a, had no effect on P-adrenergic receptor-G, cou- protein complex. Even in the absence of agonist, this complex key differences in the may have some inherent function. The observation that reconpling or agonist affinity. Thus, there are experimental findings regarding regions on different G protein stituted receptor- ; protein complexes without agonist ; have GTPaseactivity that is not seen with the G protein alone a subunits of interaction with their cognate receptors. These findings provide a rationale for the study of multiple receptor Kurose et al., 1991 ; is consistent with thisidea. Thus, receptor discern varia- plus peptide representsthe"pristine" highaffinityagonist systems to elucidate a general mechanism and to tions on the common theme. binding state. It is of interest that the ability of a given peptide to block the The fact that homologous peptides from the sequence of ai had no effect on agonist affinity Table 111 ; suggests that short coupling between the P-adrenergic receptor and G, Fig. 1 ; is proteins. peptide sequences carry a surprising degree of specificity. An dependent upon the environment surrounding these average of40%of the amino acids of the carboxyl-terminal Thus, while the a, peptide 354-372 blocks p-adrenergic stimuthus, the specificity lation of adenylyl cyclase in both permeable cells and memregion are identical between a, and ai; determinants must reside in the unique residues of the se- branes, the carboxyl-terminal peptide, 384-394, is capable of quence. Peptide proton NMR and peptide substitution studies blocking a, activation by the activated P-receptor only when in have shown that a P-turn at the carboxyl terminus of at involv- a near native environment. Furthermore, the carboxyl-termiing Gly348, Leu349, and Phe350 critical for the peptide- nal peptide appears to be disrupting only the "tightlycoupled is induced stabilization of active metarhodopsin I1 Dratz et al., state" of the P receptor-G, -adenylyl cyclase complex. Two possible reasons for this discrepancy exist. First, it is 1993 ; . It may be possible t o extrapolate from these structural studies on rhodopsin-G, interaction to the P-adrenergic recep- possible that disruptionof the membrane andcytoskeletal en.

Seeking to amend the initiative, citing a lack of transparency, potential conflicts of interest among grant reviewers, and a desire to ensure that any therapies developed will be affordable. Zach Hall, the interim president of the institute, said that the proposed changes "would seriously impede our ability to do our science haven't even gotten going, and already it's like they're crying, `Foul!'" According to Harvard's Melton, the only way to ensure steady progress in this emerging field is to have a consistent national policy. "In general, I'm not a big fan of state-led initiatives, because I think this is a federal issue, " he said. "Either this research should go forward or it shouldn't. But if it should, our present policies make no sense at all, because their only consequence is to make the research go more slowly and ginger. J. Failure to appear for or cooperate in any required step in the selection or background process, or any other act of non-compliance in the selection or background process; K. Failure to appear for or to pass a required examination or test; L. A Military discharge under less than honorable conditions; or having received a general court martial or more severe, Military disciplinary action; or having received other, lesser Military disciplinary actions on multiple occasions, especially for the same or similar offenses; M. Medical or psychological disorders to include, but not limited to, certain awarded disabilities, certain previous or current psychological treatments or confinements, certain physical and or mental disabilities which could pose a direct threat to the health and safety of the employee, coworkers, or the public; N. Addictive or compulsive gaming or gambling; O. Racial, ethnic or social intolerance; P. Failure to file or pay taxes; Q. Lack of the ability or desire to obtain and retain a valid Ohio Driver License; V. Probable Candidate Disqualifiers The following occurrences or incidents in a candidate's background will likely result in disqualification of the candidate from the selection process. A. A history of traffic accident involvement indicating a lack of defensive driving skills or ability; B. Poor credit history such as a low credit score, a history of financial problems, wage garnishments, bankruptcy, poor payment records, collections, late payments; C. A monetary lifestyle which is currently dependent upon a superior income compared to the income of a Police employee; or the inability to adequately survive on the starting salary of a Police employee; or debt-to-income problems; D. Poor employment history including, but not limited to, certain terminations; certain resignations, particularly in lieu of discharge; poor attendance records; history of tardiness; poor quality of work; poor quantity of work; the inability to get along with superiors, subordinates or peers; or poor disciplinary records. Orbiter 3700 Rotating Gamma Inc. , Des Plaines, IL and CT with a GE 9800 CT and 1 .5-T Medical Systems, Milwaukee and ginkgo.
Nursing mothers there have been no studies conducted with genotropin in nursing mothers.

Please read these instructions completely before using the GENOTROPIN PEN 12. If there is anything you do not understand or cannot do, call the toll-free number listed at the end of these instructions. If you have any questions about your dose or your treatment with GENOTROPIN, call your healthcare provider. GENOTROPIN PEN 12 is a device used to mix and inject doses of GENOTROPIN Lyophilized Powder somatropin [rDNA origin] for injection ; . Use this device only for administration of GENOTROPIN and ginseng. TAX RATE YEARS ENDED DECEMBER 31, 2000 1999 statutory rate Effect of Puerto Rico and Ireland manufacturing operations Research credits Goodwill amortization Goodwill impairment Gain on sale of business Other, net Effective tax rate 35.0.
Date Effective July 1, 2007 Material Superseded Remove the following pages from Chapter III of the Prescribed Drugs Manual and destroy them: Page Contents pp. 1-3 ; 3, 5, 9, * NCPDP Version 5.1 Payer Sheet 47-61 * Date March 1, 2006 January 1, 2006 March 1, 2006 1 March 1, 2006 June 25, 2005 March 1, 2006 and gleevec.

It unfit for human consumption. There are no good plastic containers for holding these oils and maintaining their quality. Insist on opaqued glass bottles. In a later BioSan pamphlet is the following: "Where We Went Wrong - Modern methods have made the production of fats and oils cost-effective. Cooking the seeds, crushing them mechanically, and then running the resulting mash through a giant press, or passing it through a chemical solvent, extracts every drop. The fact that these harsh manufacturing procedures chemically alter molecular structure is ignored. "In the refining process, caustic chemicals remove important free fatty acids, phospholipids, carotenoids and natural antioxidants. The oil is then chemically bleached, deodorized and `winterized.' Chemical antioxidants, stabilizers and preservatives are added. But there's worse to come. Hydrogenated Oils - Hydrogenation saturates all fatty acids with hydrogen. Using a metal catalyst, tremendous pressure is applied at temperatures exceeding 4000 F. for up to 8 hours. Because the final product is inert dead ; , it doesn't spoil. But it contains chemicallyaltered bits of fatty acids, which the body doesn't know how to handle, and traces of metal catalysts. "Partial Hydrogenation - A liquid oil is made solid or semisolid by adjusting the length of the process. Margarine and shortening are partially hydrogenated. Partial hydrogenation is worse than full hydrogenation. Here's why: "Molecules become hydrogenated erratically, leaving behind dangerously altered substances when the process is halted. Many are harmful. "Why You Should be Concerned - Over half 57% ; of our dietary fat comes from processed fats and oils. It has been established that these alien fats do not provide the Essential Fatty Acids EFAs ; the body requires every day, and we know they cannot be efficiently metabolized by the body." I haven't seen the study that produced the 57% figure quoted above, but I'd wager that far, far more than 57% of our dietary fat comes from processed fats and oils! Ray Peat, Ph.D. in Townsend Letters for Doctors, February March 1989, in a letter, warns folks against taking Linseed Oils in the amounts advocated by Udo Erasmus in Fats and Oils. Peat says that large quantities of such oils are known to cause: impaired brain development and learning; damage to skin and bones; accelerated aging and age-pigment accumulation; damage to the circulatory system; increased cancer incidence; suppressed immunity; and endocrine dysfunction. I suspect that differences lie in how deficient each person is in essential fatty acids and also in how well they absorb and utilize them. A doctor who gives three to six capsules of Oil of Evening Primrose to arthritics is undoubtedly doing the correct thing, but there are probably many arthritics or former arthritics, like myself, and cancer victims, whose tissues have become so starved for essential fatty acids that Udo Erasmus' quantities are easily and safely taken. Evidence also seems to exist that men need more of certain Essential Fatty Acids EFA ; than do women. I suspect, too, that we of the World War II vintage, and after, belong to a special class of humans wrongly sold on margarines and other so-called polyunsaturates for all our "health" needs. Some folks unquestionably get by on just a good diet, containing the right fatty acids, or ingredients convertible to them. A few small capsules per day of the right oils may suffice for others. Arthritics -- I beginning to believe -- and this needs verification by lots of patients -- probably require larger quantities of essential fatty acids, in the tablespoons per day range and genotropin.

32 Ask the Experts. Hair Workshop. Brussels, Belgium 1998. Second National Scientific Meeting of the Australasian hair and Wool Research Society, Perth 1999 Hair Disorders. Festschrift for Dr Rodney Dawber 2000. Cutaneous Biology and Endocrinology Workshop. Melbourne, 2002. Alopecia areata and cicatricial alopecia. Inaugural Meeting Australasian Society for Dermatology Research, Sydney, May 2004. Clinical and Laboratory Research IX International Congress of Dermatology, Beijing, May 2004. Hair Diseases 1 and 2. Forth Intercontinental Meeting of Hair Research Societies, Berlin, 2004. Common disorders of the hair and scalp Forth Intercontinental Meeting of Hair Research Societies, Berlin, 2004. Diagnosis of difficult cases from clinic to therapy Research Grants Australian dermatology research and education foundation, 1999-2001. Treatment of scarring alopecia Scientific Research Fund of the Australasian College of Dermatologists, 1999-2001. Genetics of alopecia areata University of Melbourne Postgraduate Medical Research Fellow, 1998. Clinical Features of Loose Anagen Syndrome Dr Alvin Chong ; Research Grant Skin and Cancer Foundation, 1999-2000. Genetics of Loose Anagen Syndrome Research Grant Glaxo Welcome, 1999-2001. Management of male androgenetic alopecia Research Grant Merck Sharpe and Dohme, 1999-2001. The relationship between scalp photography and patient compliance in the management of male androgenetic alopecia NHMRC, 1999-2001. Prevention of Hospital Acquired Pressure Ulcers: a randomised controlled trial in the use of a sheepskin underlay Scientific Research Fund of the Australasian College of Dermatologists, 2001-2002. Genetics of Hereditary Hypotrichosis Tarda Research Grant Skin and Cancer Foundation, 2001-2002 . Gene Linkage of Pili AnnulatiScientific Research Fund of the Australasian College of Dermatologists, 2002-2003. Genetic Fine Mapping of Pili Annulati National Alopecia Areata Foundation of America, 2002-2004. Genetic association studies of candidate genes in alopecia areata and gliadel. Su1.124 - Immunohistochemical Localization of Interleukin-6 in Pancreatitis and Normal Pancreas. M. Jablonowska, 1 H. Milnerowicz, 1 J. Rabczynski, 2 S. Milnerowicz.3 1Departament of Biomedical and Environmental Analyses, Wroclaw University of Medicine, Wroclaw, Poland; 2 Department of Pathological Anatomy, Wroclaw University of Medicine, Wroclaw, Poland; 3Department and Clinic of Su1.129 - Eosinophilic Esophagitis EE ; : Improved Clinical Gastointestinal and General Surgery, Wroclaw University of Responses without a Concomitant Reduction in Esophageal Medicine, Wroclaw, Poland. Eosinophilic Infiltration. F. M. Schaffer, R. B. Pillai, K. A. Hetherington, R. Shannon, T. Tumor Su1.125 - Tumor Derived TGF-beta Suppresses InflammaC. Hulsey, D. Lewin, S. N. Khubchandani, V. Tolia. 1Pediatric tion Dependent Colon Cancer Development by Inducing Pulmonary, Allergy, and Immunology, MUSC, Charleston, SC, Tumor FoxP3 in Tumor Infiltrating CD4 + T Cells. USA; 2Pediatric Gastroenterology, MUSC, Charleston, SC, 1 Becker, M. C. Fantini, C. Schramm, A. Nikolaev, P. R. USA; 3Pediatrics, MUSC, Charleston, SC, USA; 4Pediatric Galle, 1 M. F. Neurath.1 1I. Dept. of Medicine, University of Gastroenterology, MUSC, Charleston, SC, USA; 5Pediatric Mainz, Mainz, Germany. Epidimiology, MUSC, Charleston, SC, USA; 6Pathology, MUSC, Charleston, SC, USA; 7Gastroenterology, Wayne State + Su1.126 - Cross-Linking of Lipid Rafts on CD4 T Cells School of Medicine, Detroit, MI, USA; 8Gastroenterology, Wayne State School of Medicine, Detroit, MI, USA. by an Epithelial Lectin, Galectin-4, Contributes to the Exacerbation of Intestinal Inflammation. K. Shirane, 1 A. Hokama, 1 Y. Shimomura, 1 A. Ogawa, 1 M. Yoshida, 2 S. T. Rietdijk, 3 S. B. Snapper, 4 C. Terhorst, 3 R. S. Blumberg, 2 A. Mizoguchi.1 1Department of Pathology, Massachusetts General Hospital, Boston, MA, USA; 2Division of Gastroenterology, Brigham and Women's Hospital, Boston, MA, USA; 3Department of Immunology, Beth Israel Deaconess Medical Center, Boston, MA, USA; 4Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Intracellular perforin and IFN- were detected following 72 h of culture with rhu IL-12 100 pg ml ; and rhu IL-15 1 ng ml ; with Brefeldin A added during the last 5 h of culture. Staining was performed using Cytofix Cytoperm intracellular staining reagents according to the protocol supplied by the manufacturer. Intracellular proteins were detected using PE-conjugated mAb to human perforin BD Biosciences PharMingen ; and FITC-conjugated antibody to bovine IFN- Serotec ; . Additional samples were also stained with FITC- and PE-conjugated isotype-matched controls. Samples were fixed using 2% buffered paraformaldehyde and adhered to poly-L-lysine-coated slides by cytospin. Nuclei were counterstained with Slowfade 4 , 6-diamidino-2-phenylindole Molecular Probes, Eugene, OR ; , and flourescently labeled proteins were visualized using a Zeiss laser-scanning confocal microscope [Optical Imaging Core, University of Texas Medical Branch UTMB ; , Galveston] and glucagon.